MaRS’ EXCITE Announces First Participants Round

Toronto innovation hub MaRS Discovery District has selected the first three companies to participate in its Excellence in Clinical Innovation and Technology Evaluation (EXCITE) program, which accelerates the adoption of breakthrough medical technologies. The companies are: ApneaDx Inc., a developer of a home-based device for diagnosing sleep apnea, Medtronic of Canada Ltd., a developer of treatments for drug-resistant hypertension, and Rna Diagnostics Inc., a developer of a diagnostic tool to improve breast cancer treatment outcomes.

CanadaNorth AmericaBriefs